Anti-Restenosis After AMI by Erythropoietin

Kyoto Prefectural University of Medicine

Status and phase

Unknown

Phase 4

Conditions

Acute Myocardial Infarction

Treatments

Drug: Erythropoietin

Study type

Interventional

Funder types

Other

Identifiers

NCT00423020

EPOC-AMI 2006

Details and patient eligibility

About

The EPOC-AMI study is to assess the safety and the efficacy of systemic administration of erythropoietin for inhibition of neointimal hyperplasia after stent implantation in the patients with acute myocardial infarction

Full description

Stents coated with sirolimus or paclitaxel have been shown to significantly reduce restenosis in selected coronary lesions. However, the potential risk of late stent thrombosis forces prolonged treatment of dual anti-platelet regimen to all the patients after implantation of drug eluting stents. Patients with acute myocardial infarction may have uncertain clinical characteristics, such as occult bleeding focus or further need for surgical procedures. Thus, bare metal stent is considerably alternative for primary PCI after AMI and there remain an appreciable number of patients at risk for restenosis. Use of systemic pharmacological therapy to inhibit coronary stent restenosis of bare metal stent has been largely unsuccessful. We have reported that erythropoietin could enhance reendothelialization leading to inhibition of in-stent restenosis by directly protecting endothelial apoptosis and mobilizing endothelial progenitors. The EPOC-AMI study is designed to assess the safety and the efficacy of systemic administration of erythropoietin aiming inhibition of neointimal hyperplasia after stent implantation in the patients with acute myocardial infarction.

Sex

All

Ages

20 to 79 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Clinical diagnosis of acute myocardial infarction within 12hrs of symptom onset.
Succeeded reperfusion due to primary PCI accomplished bare metal stent

Exclusion criteria

Patients with cardiogenic shock (e.g. systolic BP<80mmHg,use of catecholamine, use of IABP)
Patients with anemia required transfusion
Patients who are unwilling or unable to comply with the trial protocol